SCHEMBL1364607

SCHEMBL1364607

NNC(=O)c1ccc(CO)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.61
CYP3A4 P08684 2/20 0.61
KDM5A P29375 1/20 0.61
BLM P54132 1/20 0.61
GFER P55789 1/20 0.61
PMP22 Q01453 1/20 0.61
HIF1A Q16665 1/20 0.61
ALDH1A1 P00352 8/20 0.59
MAPT P10636 7/20 0.59
KDM4E B2RXH2 5/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
OGG1 O15527 1/20 0.59
LMNA P02545 1/20 0.59
CYP1A2 P05177 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2A6 P11509 1/20 0.54
CYP2C19 P33261 1/20 0.54
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2678949 0.85 MPO (0.80) MPOCYP3A4KDM5ABLMGFER
SCHEMBL8239529 0.85 MPO (0.50) MPOCYP3A4KDM5ABLMGFER
SCHEMBL343630 0.85 MPO (0.80) MPOCYP3A4KDM5ABLMGFER
SCHEMBL11139882 0.84 MPO (0.64) MPOCYP3A4KDM5ABLMGFER
SCHEMBL28188923 0.83 MPO (0.76) MPOCYP3A4KDM5ABLMGFER
SCHEMBL27556167 0.82 MPO (0.61) MPOCYP3A4KDM5ABLMGFER
SCHEMBL4411013 0.82 HDAC3 (0.73) MPOCYP3A4KDM5ABLMGFER
SCHEMBL20424311 0.82 HDAC6 (0.67) HDAC3HDAC6NCOR2
SCHEMBL20493785 0.81 MPO (0.55) MPOCYP3A4KDM5ABLMGFER
SCHEMBL1535943 0.80 PLK1 (0.70) MPOCYP3A4KDM5ABLMGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed
US-20140363457-A1 2-THIO-1,3,4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS ALLERGAN, INC. 2014-12-11 US disclosed
US-8846729-B2 2-thio-1,3,4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators ALLERGAN, INC. (US) 2014-09-30 US disclosed
WO-2014078197-A1 2-THIO-1,3,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS ALLERGAN, INC. (US) 2014-05-22 WO disclosed
WO-2014078200-A1 2-THIO-1,3,4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS ALLERGAN, INC. (US) 2014-05-22 WO disclosed
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2010-02-18 US disclosed
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2010-02-18 US disclosed
US-20090253758-A1 Selective androgen receptor modulators ELLIPSES PHARMA LTD (GB) 2009-10-08 US disclosed
US-20090253758-A1 Selective androgen receptor modulators ELLIPSES PHARMA LTD (GB) 2009-10-08 US disclosed
US-20090253758-A1 Selective androgen receptor modulators ELLIPSES PHARMA LTD (GB) 2009-10-08 US disclosed
WO-2009105214-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2009-08-27 WO disclosed
EP-1309730-B1 NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES NANOGEN RECOGNOMICS GMBH (DE) 2008-11-26 EP disclosed
EP-1309730-B1 NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES NANOGEN RECOGNOMICS GMBH (DE) 2008-11-26 EP disclosed
US-7129229-B2 Hydrazide building blocks and hydrazide modified biomolecules NANOGEN RECOGNOMICS GMBH (DE) 2006-10-31 US disclosed
US-20040087807-A1 Macromolecules having hydrazide attachment moieties and reagents for their production SANOFI-AVENTIS S.A. (FR) 2004-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, IGF1R MPO 4835/4885CYP3A4 1229/4885KDM5A 1477/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP MPO 408/4885CYP3A4 2636/4885KDM5A 1405/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP MPO 386/4885CYP3A4 2609/4885KDM5A 1139/4885
US-20140363457-A1 2-THIO-1,3,4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS S1PR1, S1PR3, S1PR2 MPO 4559/4885CYP3A4 1943/4885KDM5A 3820/4885
US-20040087807-A1 Macromolecules having hydrazide attachment moieties and reagents for their production DNPEP, HPSE, HLCS MPO 547/4885CYP3A4 2319/4885KDM5A 1194/4885
US-20090253758-A1 Selective androgen receptor modulators AR, SHBG, GPR119 MPO 4867/4885CYP3A4 1339/4885KDM5A 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.